Medora is developed with clinicians in a working allergy practice and judged by one standard: does it hold up on a real clinic day.
Nasal congestion and sneezing for one month. Eyes itchy and watery. History of mild intermittent asthma.
Source: patient, 00:42Immunotherapy protocols, cross-reactivity discussions and pertinent negatives are dense. Medora is built for that vocabulary from the first draft.
Returns for follow-up of seasonal rhinitis. Nasal congestion and sneezing, worse in spring. Using intranasal steroid most days.
No wheeze at rest. No night cough. No hives or swelling.
Each note is reviewed and signed by the provider who saw the patient. Their edits are how the drafts improve.
Allergic rhinitis. Cetirizine, fluticasone. Improving.
Mild intermittent asthma. Peanut allergy, epinephrine on hand.
Medora is not a multi-specialty tool with an allergy add-on. Every product decision is made for allergy and immunology.
New versions are measured on data they were not trained on before they ship.
Clinicians review outputs on real clinic days, not only demo data.
A change ships only after it passes both.
Pankaj Sabharwal, founder, on why allergy needs its own system, and what one system for the whole allergy practice looks like.
14-day free trial, no card to start. Then $99 per provider per month.